Table 4.
HDAC Class | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
I | IIA | IIB | IV | |||||||||
HDACi | 1 | 2 | 3 | 8 | 4 | 5 | 7 | 9 | 6 | 10 | 11 | Diseases studied |
Vorinostat | + | + | + | + | + | + | + | + | + | + | + | 29.7% RR in CTCL (Olsen et al 2007b) FDA approved in CTCL |
Panobinostat | + | + | + | + | + | + | + | + | + | + | + | 40% OOR in phase I and 21% phase II in HL (Buglio & Younes 2010). Currently in trials for PTCL |
Belinostat | + | + | + | + | + | + | + | + | + | + | + | 0 complete response, 5 stable disease in phase I in haematological malignancies (Gimsing et al 2008) Currently phase III PTCL |
NVP-LAQ824 | + | + | + | + | + | + | + | + | + | + | + | 3/39 stable disease in treated solid tumours (De Bono et al 2008). In trial for multiple myeloma |
Depsipeptide | + | + | + | + | 34% RR in CTCL (Whittaker et al 2010). Approved CTCL | |||||||
Entinostat | + | + | Solid tumours 2/27 partial responses (Gore et al 2008). Currently phase II in Hodgkin lymphoma | |||||||||
Mocetinostat | + | + | + | − | − | − | − | + | Phase I: 3/23 complete responses in leukaemia (Garcia-Manero et al 2008b) |
HDAC, histone deactylase; HDACi, histone deactylase inhibitors; CTCL, Cutaneous T-cell lymphoma; PTCL, peripheral T-cell lymphoma;FDA, US Food and Drug Administration.